Global Information
회사소개 | 문의 | 비교리스트

간질 치료제 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2019-2027년)

Epilepsy Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

리서치사 Transparency Market Research
발행일 2019년 05월 상품 코드 881230
페이지 정보 영문 166 Pages
가격
US $ 5,795 ₩ 6,886,000 PDF (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 인쇄는 가능하지만, 전체 페이지 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 8,795 ₩ 10,451,000 PDF (5-user License) help
5명까지 공유하여 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 전체 페이지 인쇄는 1명당 1회로 한정하며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 11,795 ₩ 14,017,000 PDF (Corporate License) help
기업 내 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


간질 치료제 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2019-2027년) Epilepsy Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027
발행일 : 2019년 05월 페이지 정보 : 영문 166 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 간질 치료제(Epilepsy Therapeutics) 시장에 대해 조사했으며, 시장 동향과 기회, 성장 촉진요인 및 저해요인, 제품·유통채널·지역별 시장 분석, 경쟁 구도, 주요 기업 개요 등의 정보를 제공합니다.

목차

제1장 서론

  • 시장 정의와 범위
  • 시장 세분화
  • 주요 조사 목적
  • 조사 하이라이트

제2장 전제조건과 조사 방법

제3장 주요 요약 : 세계의 간질 치료제 시장

제4장 시장 개요

  • 서론
    • 제품 정의
    • 산업의 진화/발전
  • 개요
  • 시장 역학
    • 성장 촉진요인
    • 성장 저해요인
    • 시장 기회
  • 세계의 간질 치료제 시장 분석 및 예측
    • 시장 매출 예측(US$ Mn)

제5장 시장 전망

  • 파이프라인
  • 간질 역학
  • 주요 산업 이벤트

제6장 세계의 간질 치료제 시장 분석 및 예측 : 제품별

  • 서론과 정의
  • 주요 조사결과/개발
  • 시장 판매 예측
    • 제1세대
    • 제2세대
    • 제3세대
  • 시장의 매력

제7장 세계의 간질 치료제 시장 분석 및 예측 : 유통채널별

  • 서론과 정의
  • 주요 조사결과/개발
  • 시장 판매 예측
    • 병원 약국
    • 소매 약국
    • 온라인 약국
  • 시장의 매력

제8장 세계의 간질 치료제 시장 분석 및 예측 : 지역별

  • 주요 조사결과
  • 시장 판매 예측
    • 북미
    • 유럽
    • 아시아태평양
    • 라틴아메리카
    • 중동 및 아프리카
  • 시장의 매력

제9장 북미

제10장 유럽

제11장 아시아태평양

제12장 라틴아메리카

제13장 중동 및 아프리카

제14장 경쟁 구도

  • 시장 진출기업 : 경쟁 매트릭스(Tier 및 기업 규모별)
  • 기업별 시장 점유율 분석
  • 기업 개요
    • Pfizer, Inc.
    • UCB SA
    • Bausch Health Companies Inc.
    • Novartis AG
    • GlaxoSmithKline plc.
    • Teva Pharmaceutical Industries Ltd.
    • Sunovion Pharmaceuticals Inc.
    • Eisai Co., Ltd.
    • Upsher-Smith Laboratories, LLC.
    • Amneal Pharmaceuticals LLC.
LSH 19.07.16

List of Tables

  • Table 01: Global Epilepsy Therapeutics Market Value (US$ Mn) Forecast, by Product, 2017-2027
  • Table 02: Global Epilepsy Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2027
  • Table 03: Global Epilepsy Therapeutics Market Value (US$ Mn) Forecast, by Region, 2017-2027
  • Table 04: North America Epilepsy Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017-2027
  • Table 05: North America Epilepsy Therapeutics Market Value (US$ Mn) Forecast, by Product, 2017-2027
  • Table 06: North America Epilepsy Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel , 2017-2027
  • Table 07: Europe Epilepsy Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • Table 08: Europe Epilepsy Therapeutics Market Value (US$ Mn) Forecast, by Product, 2017-2027
  • Table 09: Europe Epilepsy Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2027
  • Table 10: Asia Pacific Epilepsy Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • Table 11: Asia Pacific Epilepsy Therapeutics Market Value (US$ Mn) Forecast, by Product, 2017-2027
  • Table 12: Asia Pacific Epilepsy Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2027
  • Table 13: Latin America Epilepsy Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • Table 14: Latin America Epilepsy Therapeutics Market Value (US$ Mn) Forecast, by Product, 2017-2027
  • Table 15: Latin America Epilepsy Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2027
  • Table 16: Middle East & Africa Epilepsy Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • Table 17: Middle East & Africa Epilepsy Therapeutics Market Value (US$ Mn) Forecast, by Product, 2017-2027
  • Table 18: Middle East & Africa Epilepsy Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2027

Description

Table Of Content

List Of Table

List Of Charts / Figures

List of Figure

  • Figure 01: Global Epilepsy Therapeutics Market Value (US$ Mn) and Distribution, by Region, 2018 and 2027
  • Figure 02: Global Epilepsy Therapeutics Market Value (US$ Mn), by Product, 2018
  • Figure 03: Global Epilepsy Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2027
  • Figure 04: Global Epilepsy Therapeutics Market Value Share (%), by Product, 2018 and 2027
  • Figure 05: Global Epilepsy Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by First Generation Epilepsy Therapeutics, 2017-2027
  • Figure 06: Global Epilepsy Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Second Generation Epilepsy Therapeutics, 2017-2027
  • Figure 07: Global Epilepsy Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Third Generation Epilepsy Therapeutics, 2017-2027
  • Figure 08: Global Epilepsy Therapeutics Market Attractiveness Analysis, by Product, 2019-2027
  • Figure 09: Global Epilepsy Therapeutics Market Value Share, by Distribution Channel, 2018 and 2027
  • Figure 10: Global Epilepsy Therapeutics Market Attractiveness, by Distribution Channel, 2019-2027
  • Figure 11: Global Epilepsy Therapeutics Market Value (US$ Mn) and Y-o-Y Growth, by Hospital Pharmacy, 2017-2027
  • Figure 12: Global Epilepsy Therapeutics Market Value (US$ Mn) and Y-o-Y Growth, by Retail Pharmacy , 2017-2027
  • Figure 13: Global Epilepsy Therapeutics Market Value (US$ Mn) and Y-o-Y Growth, by Online Pharmacy, 2017-2027
  • Figure 14: Global Epilepsy Therapeutics Market Value Share, by Region, 2018 and 2027
  • Figure 15: Global Epilepsy Therapeutics Market Attractiveness, by Region, 2019-2027
  • Figure 16: North America Epilepsy Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2027
  • Figure 17: North America Epilepsy Therapeutics Market Value Share (%), by Country, 2018 and 2027
  • Figure 18: North America Epilepsy Therapeutics Market Attractiveness, by Country, 2019-2027
  • Figure 19: North America Epilepsy Therapeutics Market Value Share, by Product, 2018 and 2027
  • Figure 20: North America Epilepsy Therapeutics Market Attractiveness, by Product, 2019-2027
  • Figure 21: North America Epilepsy Therapeutics Market Value Share Analysis, by Distribution Channel, 2018 and 2027
  • Figure 22: North America Epilepsy Therapeutics Market Attractiveness, by Distribution Channel, 2019-2027
  • Figure 23: Europe Epilepsy Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2027
  • Figure 24: Europe Epilepsy Therapeutics Market Value Share (%), by Country / Sub-region, 2018 and 2027
  • Figure 25: Europe Epilepsy Therapeutics Market Attractiveness, by Country / Sub-region, 2019-2027
  • Figure 26: Europe Epilepsy Therapeutics Market Value Share, by Product, 2018 and 2027
  • Figure 27: Europe Epilepsy Therapeutics Market Attractiveness, by Product, 2019-2027
  • Figure 28: Europe Epilepsy Therapeutics Market Value Share Analysis, by Distribution Channel, 2018 and 2027
  • Figure 29: Europe Epilepsy Therapeutics Market Attractiveness, by Distribution Channel, 2019-2027
  • Figure 30: Asia Pacific Epilepsy Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2027
  • Figure 31: Asia Pacific Epilepsy Therapeutics Market Value Share (%), by Country/Sub-region, 2018 and 2027
  • Figure 32: Asia Pacific Epilepsy Therapeutics Market Attractiveness, by Country/Sub-region, 2019-2027
  • Figure 33: Asia Pacific Epilepsy Therapeutics Market Value Share, by Product, 2018 and 2027
  • Figure 34: Asia Pacific Epilepsy Therapeutics Market Attractiveness, by Product, 2019-2027
  • Figure 35: Asia Pacific Epilepsy Therapeutics Market Value Share Analysis, by Distribution Channel, 2018 and 2027
  • Figure 36: Asia Pacific Epilepsy Therapeutics Market Attractiveness, by Distribution Channel, 2019-2027
  • Figure 37: Latin America Epilepsy Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2027
  • Figure 38: Latin America Epilepsy Therapeutics Market Value Share (%), by Country / Sub-region, 2018 and 2027
  • Figure 39: Europe Epilepsy Therapeutics Market Attractiveness, by Country / Sub-region, 2019-2027
  • Figure 40: Latin America Epilepsy Therapeutics Market Value Share, by Product, 2018 and 2027
  • Figure 41: Latin America Epilepsy Therapeutics Market Attractiveness, by Product, 2019-2027
  • Figure 42: Latin America Epilepsy Therapeutics Market Value Share Analysis, by Distribution Channel, 2018 and 2027
  • Figure 43: Latin America Epilepsy Therapeutics Market Attractiveness, by Distribution Channel, 2019-2027
  • Figure 44: Middle East & Africa Epilepsy Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2027
  • Figure 45: Middle East & Africa Epilepsy Therapeutics Market Value Share (%), by Country/Sub-region, 2018 and 2027
  • Figure 46: Middle East & Africa Epilepsy Therapeutics Market Attractiveness, by Country/Sub-region, 2019-2027
  • Figure 47: Middle East & Africa Epilepsy Therapeutics Market Value Share, by Product, 2018 and 2027
  • Figure 48: Middle East & Africa Epilepsy Therapeutics Market Attractiveness, by Product, 2019-2027
  • Figure 49: Middle East & Africa Epilepsy Therapeutics Market Value Share Analysis, by Distribution Channel, 2018 and 2027
  • Figure 50: Middle East & Africa Epilepsy Therapeutics Market Attractiveness, by Distribution Channel, 2019-2027
  • Figure 51: Pfizer, Inc. Revenue (US$ Mn) & Y-o-Y Growth (%), 2016-2018
  • Figure 52: Pfizer, Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016-2018
  • Figure 53: Pfizer, Inc. Breakdown of Net Sales, by Geography 2018
  • Figure 54: Pfizer, Inc. Breakdown of Net Sales, by Business Segments (%), 2018
  • Figure 55: Bausch Health Companies Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2015-2017
  • Figure 56: Bausch Health Companies Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015-2017
  • Figure 57: Bausch Health Companies Inc. Breakdown of Net Sales (%), by Region, 2017
  • Figure 58: Bausch Health Companies Inc. Breakdown of Revenues(%), by Product Category, 2017
  • Figure 59: UCB S.A. Revenue (US$ Bn) and Y-o-Y Growth (%), 2016-2018
  • Figure 60: UCB S.A. R&D Intensity and Sales & Marketing Intensity - Company Level, 2017-2018
  • Figure 61: UCB S.A. Breakdown of Net Sales, by Region, 2018
  • Figure 62: UCB S.A. Breakdown of Net Sales, by Therapeutic Area, 2018
  • Figure 63: Novartis AG Revenue (US$ Bn) and Y-o-Y Growth (%), 2016-2018
  • Figure 64: Novartis AG R&D Intensity and Sales & Marketing Intensity - Company Level, 2017-2018
  • Figure 65: Novartis AG Breakdown of Net Sales, by Region, 2018
  • Figure 66: Novartis AG Breakdown of Net Sales, by Business Segment, 2018
  • Figure 67: GlaxoSmithKline plc. Sales Revenue (US$ Mn) & Y-o-Y Growth (%), 2016-2018
  • Figure 68: GlaxoSmithKline plc. Breakdown of R&D Expenditure (US$ Mn), 2016-2018
  • Figure 69: GlaxoSmithKline plc. Breakdown of Net Sales, by Region, 2018
  • Figure 70: GlaxoSmithKline plc. Breakdown of Net Sales, by Business Segments, 2018
  • Figure 71: Teva Pharmaceutical Industries Ltd. Revenue (US$ Mn) & Y-o-Y Growth (%), 2015-2018
  • Figure 72: Teva Pharmaceutical Industries Ltd. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015-2018
  • Figure 73: Sumitomo Dainippon Pharma Co., Ltd Pharmaceuticals Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2015-2017
  • Figure 74: Sumitomo Dainippon Pharma Co., Ltd R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015-2017
  • Figure 75: Sumitomo Dainippon Pharma Co., Ltd Breakdown of Pharmaceuticals Business Net Sales (%), by Region, 2017
  • Figure 76: Sumitomo Dainippon Pharma Co., Ltd Breakdown of Net Sales (%), by Product Segment, 2017
  • Figure 77: Eisai Co., Ltd., Revenue (US$ Mn), 2017-2018
  • Figure 78: Eisai Co., Ltd., R&D Expenses (US$ Mn), 2017-2018
  • Figure 79: Eisai Co., Ltd., Breakdown of Net Sales (%), by Region, 2018
  • Figure 80: Sawai Pharmaceutical, Co.,Ltd., Revenue (US$ Mn), 2017-2018
  • Figure 81: Sawai Pharmaceutical, Co.,Ltd., Ltd, R&D Expenses (US$ Mn), 2017-2018
  • Figure 82: Sawai Pharmaceutical, Co.,Ltd., Breakdown of Net Sales (%), by Region, 2018
  • Figure 83: Amneal Pharmaceuticals LLC., Revenue (US$ Mn) & Y-o-Y Growth (%), 2016-2018
  • Figure 84: Amneal Pharmaceuticals LLC., R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016-2018

Title:
Epilepsy Therapeutics Market (Product - First Generation Epilepsy Therapeutics, Second Generation Epilepsy Therapeutics, Third Generation Epilepsy Therapeutics; Distribution Channel - Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027.

Global Epilepsy Therapeutics Market: Overview

This report analyzes the global epilepsy therapeutics market in terms of its current and future scenario. Epilepsy is a central nervous system disorder in which the brain activity becomes abnormal, thereby resulting in periods of unusual behavior or seizures, sensations, and sometimes, even loss of awareness. Epilepsy is generally diagnosed after a person has experienced at least two seizures that didn't occur due to known medical condition; for instance, extremely low blood sugar or alcohol withdrawal. The treatment of epilepsy can be carried out with antiepileptic medications (AEDs), diet therapy, and surgery. Epilepsy therapeutics or medications are the starting treatment choice for almost all patients with multiple seizures. According to American Association of Neurological Surgeons, epilepsy therapeutics are significantly effective and completely control seizures in a majority (approximately 70%) of patients. The drugs prevent seizures by decreasing the tendency of the brain cells to send excessive and confused electrical impulses.

This report on the global epilepsy therapeutics market comprises an elaborate executive summary, including a market snapshot that provides information about different segments of the market. The report also provides information and data analysis of the global market with respect to its segments based on product, distribution channel, and geography. A detailed qualitative analysis of drivers, restraints, and opportunities of the market has been provided in the market overview section. Moreover, the section comprises the company profiles with a business overview to project the competitive landscape of the market. It also provides market attractiveness analysis in terms of geography, and market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario prevailing in the epilepsy therapeutics market.

Global Epilepsy Therapeutics Market: Key Segments

Based on product, the global epilepsy therapeutics market has been segmented into first generation epilepsy therapeutics, second generation epilepsy therapeutics, and third generation epilepsy therapeutics. In terms of distribution channel, the global epilepsy therapeutics market has been classified into hospital pharmacy, retail pharmacy, and online pharmacy. The global epilepsy therapeutics market has been analyzed based on approvals and launches of products, research and developmental activities, and presence of key players in the region. Market size and forecast for each of these segments have been provided for the period of 2017 to 2027, along with their respective CAGR for the forecast period from 2019 to 2027, considering 2018 as the base year.

Global Epilepsy Therapeutics Market: Regional Outlook

In terms of region, the global epilepsy therapeutics market has been categorized into five major regions and key countries in these regions: North America (the U.S., Canada), Europe (Germany, the U.K., France, Italy, Russia, Spain, and Rest of Europe), Asia Pacific (China, India, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (GCC countries, South Africa, Israel, and Rest of Middle East & Africa). Market size and forecast for each of these regions and their key countries have been provided for the period from 2017 to 2027, along with their respective CAGR for the forecast period 2019-2027, considering 2018 as the base year. This report also covers the competitive scenario of the market in these regions.

Companies Mentioned in Report

The report profiles major players operating in the global epilepsy therapeutics market in terms of attributes such as company overview, financial overview, product portfolio, and business strategies. Major companies profiled in this report are Pfizer, Inc., UCB S.A., Bausch Health Companies Inc., Novartis AG, GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., Sunovion Pharmaceuticals Inc., Eisai Co., Upsher-Smith Laboratories, LLC., and Amneal Pharmaceuticals LLC.

The global epilepsy therapeutics market has been segmented as mentioned below:

  • Global Epilepsy Therapeutics Market, by Product
  • First Generation Epilepsy Therapeutics
  • Second Generation Epilepsy Therapeutics
  • Third Generation Epilepsy Therapeutics
  • Global Epilepsy Therapeutics Market, by Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Global Epilepsy Therapeutics Market, by Region
  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • GCC Countries
  • South Africa
  • Israel
  • Rest of Middle East & Africa

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Epilepsy Therapeutics Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Epilepsy Therapeutics Market Analysis and Forecast, 2017-2027
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Market Outlook

  • 5.1.Pipeline
  • 5.2.Epidemiology of Epilepsy
  • 5.3.Key Industry Events

6. Global Epilepsy Therapeutics Market Analysis and Forecast, by Product

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Global Epilepsy Therapeutics Market Value Forecast, by Product, 2017-2027
    • 6.3.1. First Generation Epilepsy Therapeutics
    • 6.3.2. Second Generation Epilepsy Therapeutics
    • 6.3.3. Third Generation Epilepsy Therapeutics
  • 6.4. Global Epilepsy Therapeutics Market Attractiveness, by Product

7. Global Epilepsy Therapeutics Market Analysis and Forecast, by Distribution Channel

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Global Epilepsy Therapeutics Market Value Forecast, by Distribution Channel, 2017-2027
    • 7.3.1. Hospital Pharmacy
    • 7.3.2. Retail Pharmacy
    • 7.3.3. Online Pharmacy
  • 7.4. Global Epilepsy Therapeutics Market Attractiveness, by Distribution Channel

8. Global Epilepsy Therapeutics Market Analysis and Forecast, by Region

  • 8.1. Key Findings
  • 8.2. Global Epilepsy Therapeutics Market Value Forecast, by Region
    • 8.2.1. North America
    • 8.2.2. Europe
    • 8.2.3. Asia Pacific
    • 8.2.4. Latin America
    • 8.2.5. Middle East & Africa
  • 8.3. Global Epilepsy Therapeutics Market Attractiveness, by Region

9. North America Epilepsy Therapeutics Market Analysis and Forecast

  • 9.1. Introduction
    • 9.1.1. Key Findings
  • 9.2. North America Epilepsy Therapeutics Market Value Forecast, by Product, 2017-2027
    • 9.2.1. First Generation Epilepsy Therapeutics
    • 9.2.2. Second Generation Epilepsy Therapeutics
    • 9.2.3. Third Generation Epilepsy Therapeutics
  • 9.3. North America Epilepsy Therapeutics Market Value Forecast, by Distribution Channel, 2017-2027
    • 9.3.1. Hospital Pharmacy
    • 9.3.2. Retail Pharmacy
    • 9.3.3. Online Pharmacy
  • 9.4. North America Epilepsy Therapeutics Market Value Forecast, by Country, 2017-2027
    • 9.4.1. U.S.
    • 9.4.2. Canada
  • 9.5. North America Epilepsy Therapeutics Market Attractiveness Analysis
    • 9.5.1. By Product
    • 9.5.2. By Distribution Channel
    • 9.5.3. By Country

10. Europe Epilepsy Therapeutics Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Europe Epilepsy Therapeutics Market Value Forecast, by Product, 2017-2027
    • 10.2.1. First Generation Epilepsy Therapeutics
    • 10.2.2. Second Generation Epilepsy Therapeutics
    • 10.2.3. Third Generation Epilepsy Therapeutics
  • 10.3. Europe Epilepsy Therapeutics Market Value Forecast, by Distribution Channel, 2017-2027
    • 10.3.1. Hospital Pharmacy
    • 10.3.2. Retail Pharmacy
    • 10.3.3. Online Pharmacy
  • 10.4. Europe Epilepsy Therapeutics Market Value Forecast, by Country/Sub-region, 2017-2027
    • 10.4.1. Germany
    • 10.4.2. U.K.
    • 10.4.3. France
    • 10.4.4. Spain
    • 10.4.5. Italy
    • 10.4.6. Rest of Europe
  • 10.5. Europe Epilepsy Therapeutics Market Attractiveness Analysis
    • 10.5.1. By Product
    • 10.5.2. By Distribution Channel
    • 10.5.3. By Country/Sub-region

11. Asia Pacific Epilepsy Therapeutics Market Analysis and Forecast

  • 11.1.Introduction
    • 11.1.1. Key Findings
  • 11.2. Asia Pacific Epilepsy Therapeutics Market Value Forecast, by Product, 2017-2027
    • 11.2.1. First Generation Epilepsy Therapeutics
    • 11.2.2. Second Generation Epilepsy Therapeutics
    • 11.2.3. Third Generation Epilepsy Therapeutics
  • 11.3. Asia Pacific Epilepsy Therapeutics Market Value Forecast, by Distribution Channel, 2017-2027
    • 11.3.1. Hospital Pharmacy
    • 11.3.2. Retail Pharmacy
    • 11.3.3. Online Pharmacy
  • 11.4. Asia Pacific Epilepsy Therapeutics Market Value Forecast, by Country/Sub-region, 2017-2027
    • 11.4.1. China
    • 11.4.2. Japan
    • 11.4.3. India
    • 11.4.4. Australia & New Zealand
    • 11.4.5. Rest of Asia Pacific
  • 11.5. Asia Pacific Epilepsy Therapeutics Market Attractiveness Analysis
    • 11.5.1. By Product
    • 11.5.2. By Distribution Channel
    • 11.5.3. By Country/Sub-region

12. Latin America Epilepsy Therapeutics Market Analysis and Forecast

  • 12.1.Introduction
    • 12.1.1. Key Findings
  • 12.2. Latin America Epilepsy Therapeutics Market Value Forecast, by Product, 2017-2027
    • 12.2.1. First Generation Epilepsy Therapeutics
    • 12.2.2. Second Generation Epilepsy Therapeutics
    • 12.2.3. Third Generation Epilepsy Therapeutics
  • 12.3. Latin America Epilepsy Therapeutics Market Value Forecast, by Distribution Channel, 2017-2027
    • 12.3.1. Hospital Pharmacy
    • 12.3.2. Retail Pharmacy
    • 12.3.3. Online Pharmacy
  • 12.4. Latin America Epilepsy Therapeutics Market Value Forecast, by Country/Sub-region, 2017-2027
    • 12.4.1. Brazil
    • 12.4.2. Mexico
    • 12.4.3. Rest of Latin America
  • 12.5. Latin America Epilepsy Therapeutics Market Attractiveness Analysis
    • 12.5.1. By Product
    • 12.5.2. By Distribution Channel
    • 12.5.3. By Country/Sub-region

13. Middle East & Africa Epilepsy Therapeutics Market Analysis and Forecast

  • 13.1.Introduction
    • 13.1.1. Key Findings
  • 13.2. Middle East & Africa Epilepsy Therapeutics Market Value Forecast, by Product, 2017-2027
    • 13.2.1. First Generation Epilepsy Therapeutics
    • 13.2.2. Second Generation Epilepsy Therapeutics
    • 13.2.3. Third Generation Epilepsy Therapeutics
  • 13.3. Middle East & Africa Epilepsy Therapeutics Market Value Forecast, by Distribution Channel, 2017-2027
    • 13.3.1. Hospital Pharmacy
    • 13.3.2. Retail Pharmacy
    • 13.3.3. Online Pharmacy
  • 13.4. Middle East & Africa Epilepsy Therapeutics Market Value Forecast, by Country/Sub-region, 2017-2027
    • 13.4.1. GCC Countries
    • 13.4.2. South Africa
    • 13.4.3. Israel
    • 13.4.4. Rest of Middle East & Africa
  • 13.5. Middle East & Africa Epilepsy Therapeutics Market Attractiveness Analysis
    • 13.5.1. By Product
    • 13.5.2. By Distribution Channel
    • 13.5.3. By Country/Sub-region

14. Competition Landscape

  • 14.1.Market Player - Competition Matrix (By Tier and Size of companies)
  • 14.2.Market Share Analysis By Company (2018)
  • 14.3. Company Profiles
    • 14.3.1. Pfizer, Inc.
      • 14.3.1.1 Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.1.2. Company Financials
      • 14.3.1.3.Growth Strategies
      • 14.3.1.4. SWOT Analysis
    • 14.3.2. UCB S.A.
      • 14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.2.2. Company Financials
      • 14.3.2.3. Growth Strategies
      • 14.3.2.4. SWOT Analysis
    • 14.3.3. Bausch Health Companies Inc.
      • 14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.3.2. Company Financials
      • 14.3.3.3. Growth Strategies
      • 14.3.3.4. SWOT Analysis
    • 14.3.4. Novartis AG
      • 14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.4.2. Company Financials
      • 14.3.4.3. Growth Strategies
      • 14.3.4.4. SWOT Analysis
    • 14.3.5. GlaxoSmithKline plc.
      • 14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.5.2. Company Financials
      • 14.3.5.3. Growth Strategies
      • 14.3.5.4. SWOT Analysis
    • 14.3.6. Teva Pharmaceutical Industries Ltd.
      • 14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.6.2. Company Financials
      • 14.3.6.3. Growth Strategies
      • 14.3.6.4. SWOT Analysis
    • 14.3.7. Sunovion Pharmaceuticals Inc.
      • 14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.7.2. Company Financials
      • 14.3.7.3. Growth Strategies
      • 14.3.7.4. SWOT Analysis
    • 14.3.8. Eisai Co., Ltd.
      • 14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.8.2. Company Financials
      • 14.3.8.3. Growth Strategies
      • 14.3.8.4. SWOT Analysis
    • 14.3.9. Upsher-Smith Laboratories, LLC.
      • 14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.9.2. Company Financials
      • 14.3.9.3. Growth Strategies
      • 14.3.9.4. SWOT Analysis
    • 14.3.10. Amneal Pharmaceuticals LLC.
      • 14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.10.2. Company Financials
      • 14.3.10.3. Growth Strategies
      • 14.3.10.4. SWOT Analysis
Back to Top
전화 문의
F A Q